Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

LTR Pharma fulfils first US ROXUS prescriptions as SPONTAN Phase II report completes FDA dataset

LTP: $0.440 +0.00% · MC: $86M

LTR Pharma says its first patient-specific ROXUS prescriptions were fulfilled in the US after quarter-end, following agreements with telehealth platform Shed and Strive Pharmacy. A final Phase II report confirmed SPONTAN’s six-fold faster absorption than oral vardenafil tablets and completed its FDA pharmacokinetic dataset; a Phase III study is targeted to start in the first half of 2027. The company reported approximately A$18 million in cash and no debt at quarter-end, with net operating cash outflow of approximately A$2 million.

Source announcements: 2026-10-28 08:22 to 2026-10-28 08:22 Sydney time
Story updated 2026-10-28 08:26 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments